Pure Monograph vs Allos AI
Both platforms use AI in pharma, but they sit on opposite sides of the R&D pipeline. Allos is upstream formulation science for complex generics. Pure Monograph is downstream regulatory and CMC authoring. In most programs the two are complementary rather than substitutable.
Short answer. Allos AI solves "which formulation will work" for complex generic candidates using causal AI. Pure Monograph solves "how do I document, transfer, and submit what I've already made". If you are still at bench screening, look at Allos. If you are entering CTD, tech transfer, or BMR authoring, Pure Monograph is the fit.
At a glance
| Dimension | Pure Monograph | Allos AI |
|---|---|---|
| Primary deliverable | CTD Module 3 drafts, tech transfer packages, BMRs, stability protocols, CMC intelligence | Reformulation hypotheses for complex generics via causal AI |
| Category | Regulatory authoring & CMC intelligence | Upstream formulation design |
| Regulatory output | Drafts aligned to ICH M4 / Q-series, 21 CFR, USP | Not a regulatory authoring tool |
| Pricing | Self-serve $0-$1,499/mo; request-based $7,500-$80,000 USD | Seed-stage; not public self-serve at time of writing |
| Engagement model | SaaS subscription plus concierge packages | Platform + services partnership |
| Ownership | Burrard Pharmaceutical Enterprises Ltd., Vancouver BC | Allos AI, Oxford UK ($5M seed, Dec 2025) |
When each is the right call
Pick Allos when the question is "can this drug even be formulated without a bridging study?" — particularly for complex generics with modified-release, combination, or high-potency profiles where traditional DoE screens have stalled.
Pick Pure Monograph when the question is "how do I get the formulation I already validated into a CTD and onto a receiving site". The platform assumes you have bench data in hand; Predict and Optimize features require real uploaded datasets before they produce any recommendation.
Using both in sequence
A typical workflow: Allos identifies a viable reformulation for a complex generic candidate, the sponsor validates it at bench and pilot scale, then Pure Monograph authors the ICH Q1-based stability protocol, the ICH Q5E comparability package, the 21 CFR 211.188 BMR, and the ICH M4Q / Module 3 narrative for submission. Two tools, one pipeline, zero overlap in deliverables.
Frequently asked questions
Is Pure Monograph the same kind of tool as Allos AI?
No. Allos is an upstream discovery and reformulation platform using causal AI. Pure Monograph is a downstream authoring and intelligence platform for CTD, tech transfer, BMR, and CMC work. They frequently coexist in the same program.
Where is Allos AI based and what is its current stage?
Allos AI is headquartered in Oxford, UK and raised a $5 million USD seed round in December 2025. Their focus has been formulation for complex generics where conventional trial-and-error cycles fail.
Which do I start with?
If you are still selecting a molecule or formulation, start upstream with Allos. If you are building CTD Module 3, tech transfer, or BMR content for a validated candidate, start with Pure Monograph.
Can Pure Monograph replace a discovery-stage tool?
No. Its Drug Design Lab produces scaffolds, risks, and first-experiment plans. Predict and Optimize routines are gated behind real uploaded bench data and do not replace causal or mechanistic discovery tooling.